Combination of immunotherapies with MDM2 inhibitors
US12268665B2 · kind B2 · utility
0Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2019 |
| Grant date | Apr 8, 2025 |
| Priority date | — |
| Expiry date | Oct 8, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.